Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 1, 2021

Primary Completion Date

December 16, 2022

Study Completion Date

December 16, 2022

Conditions
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Interventions
DRUG

Infigratinib

Hard gelatin capsules for oral use

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

33155

Nicklaus Children's Hospital, Miami

69120

Universitaetsklinikum Heidelberg (UKHD) - Zentrum fuer Kinder- und Jugendmedizin - Klinik Kinderheilkunde III, Heidelberg

94304

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto

20010-2916

Children's National Hospital - Brain Tumor Institute, Washington D.C.

27702-3624

Duke Cancer Institute (DCI) - The Preston Robert Tisch Brain Tumor Center, Durham

15224-1529

UPCM - Children's Hospital of Pittsburgh, Pittsburgh

T6G 2B7

University of Alberta - Stollery Children's Hospital (SCH), Edmonton

L8N 3Z5

McMaster Children's Hospital (MCH), Hamilton

M5G 1X8

University of Toronto - The Hospital for Sick Children (SickKids), Toronto

Sponsors
All Listed Sponsors
collaborator

Labcorp Corporation of America Holdings, Inc

INDUSTRY

lead

Helsinn Healthcare SA

INDUSTRY